• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Stents

Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent

May 23, 2025 By Sean Whooley

Elixir-Dynamx

Elixir Medical announced three-year results from a large randomized controlled trial of its DynamX coronary bioadaptor system. The 445-patient BIOADAPTOR trial compares DynamX to the standard of care Medtronic Resolute Onyx drug-eluting stent (DES). It took place across 34 centers in Japan, Europe and New Zealand. Data — shared this week at EuroPCR 2025 in […]

Filed Under: Cardiovascular, Clinical Trials, Implants, Stents Tagged With: Elixir Medical Corporation

Data backs Boston Scientific drug-eluting stent

April 23, 2025 By Sean Whooley

Boston Scientific Eluvia drug-eluting vascular stent system (1)

Boston Scientific today shared study data supporting the use of its Eluvia drug-eluting stent for treating PAD. The company shared multiple new clinical data sets at Charing Cross 2025 in London today. Findings reinforced the growing body of evidence supporting the Eluvia stent for treating peripheral artery disease (PAD) — particularly in the superficial femoral […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Implants, Stents, Vascular Tagged With: Boston Scientific

R3 Vascular reports first patient treated in next-gen drug-eluting scaffold study

April 22, 2025 By Sean Whooley

R3 Vascular Logo (1)

R3 Vascular announced today that a doctor treated the first patient in the ELITE-BTK pivotal trial of its drug-eluting bioresorbable scaffold. Dr. Brian DeRubertis of New York-Presbyterian and Weill Cornell Medicine treated the first patient. The trial evaluates the company’s next-generation Magnitude drug-eluting bioresorbable scaffold for below-the-knee peripheral arterial disease (PAD). Mountain View, California-based R3 […]

Filed Under: Clinical Trials, Drug-Device Combinations, Implants, Stents, Vascular Tagged With: R3 Vascular

Abbott reports sustained benefits with Esprit drug-eluting stent

November 4, 2024 By Sean Whooley

Abbott Esprit BTK

Abbott (NYSE:ABT) today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent. The everolimus-eluting resorbable scaffold system treats chronic limb-threatening ischemia (CLTI) below the knee (BTK). Abbott designed it to keep arteries open and deliver everolimus to support vessel healing prior to completely dissolving. The first-of-its-kind stent provides support to the vessel […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Implants, Stents, Vascular Tagged With: abbott

R3 Vascular wins FDA IDE for drug-eluting scaffold

November 4, 2024 By Sean Whooley

R3 Vascular Logo

R3 Vascular announced today that the FDA granted investigational device exemption (IDE) to evaluate its Magnitude drug-eluting bioresorbable scaffold. Mountain View, California-based R3 Vascular designed Magnitude for treating below-the-knee (BTK) peripheral arterial disease (PAD). With the FDA granting IDE, it can now initiate the ELITE-BTK pivotal trial for the next-generation bioresorbable scaffold. R3 Vascular makes […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Stents, Vascular Tagged With: FDA, R3 Vascular

Elixir Medical has positive data for drug-eluting bioadaptive implant

October 29, 2024 By Sean Whooley

Elixir-Dynamx

Elixir Medical announced positive data demonstrating the benefit of its DynamX coronary bioadaptor system in target lesion failure (TLF). Data highlighted the success of DynamX compared to Medtronic’s Resolute Onyx zotarolimus drug-eluting stent (DES). The study looked at complex patient populations within the INFINITY-SWEDEHEART randomized controlled trial. Data included an analysis of patients with acute […]

Filed Under: Clinical Trials, Drug-Device Combinations, Implants, Stents Tagged With: Elixir Medical Corporation

Medinol has first human implant of drug-eluting peripheral stent in Australia

October 7, 2024 By Sean Whooley

Medinol ChampioNIR drug-eluting stent

Medinol today announced the successful first-in-human implantation of its ChampioNIR drug-eluting peripheral stent. Dr. Gerard S. Goh and Dr. Thodur Vasudevan of the Alfred Hospital in Melbourne, Australia, completed the stent implant. The company says it introduces a “revolutionary advancement” in the mechanics, durability and drug delivery of peripheral drug-eluting stents. Tel Aviv, Israel-based Medinol […]

Filed Under: Clinical Trials, Drug-Device Combinations, Implants, Stents, Vascular Tagged With: medinol

Reflow Medical enrolls first patient in coronary sirolimus-eluting retrievable scaffold system study

July 2, 2024 By Sean Whooley

Reflow Medical Logo

Reflow Medical announced that investigators enrolled the first patients in a trial of its Spur sirolimus-eluting retrievable scaffold system. DEEPER CORONARY evaluates the Spur Elute stent as a primary treatment for in-stent restenosis (ISR) of the coronary arteries. Spur Elute offers a treatment by transferring a proprietary drug formulation to the diseased lesion without leaving […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Implants, Stents, Vascular Tagged With: Reflow Medical

Abbott wins FDA approval for dissolving drug-eluting scaffold

April 29, 2024 By Sean Whooley

Abbott Espirit BTK

Abbott [WtwhTicker symbol=”ABT”](NYSE: ABT)[/WtwhTicker] announced today that the FDA approved its Espirit everolimus-eluting resorbable scaffold system. The Espirit scaffold treats chronic limb-threatening ischemia (CLTI) below the knee (BTK). Abbott designed it to keep arteries open and deliver everolimus to support vessel healing prior to completely dissolving. According to a news release, no stents or drug-coated […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Stents, Vascular Tagged With: abbott, FDA

Cook Medical wins DOD contract for drug-eluting stents

April 11, 2024 By Sean Whooley

Cook Medical Zilver PTX

Cook Medical announced today that the U.S. Dept. of Defense (DOD) awarded it an ECAT contract for implantable medical devices. The contract includes implantable vascular medical devices like the Zilver PTX drug-eluting peripheral stent. It also applies to the Zenith aortic endografts and associated interventional devices for treating vascular disease. Cook Medical said in a […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Stents Tagged With: cook medical, U.S. Defense Dept.

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 6
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS